Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0W0SM
|
|||
| Former ID |
DIB010067
|
|||
| Drug Name |
CRL-8131
|
|||
| Synonyms |
Flocor; RheothRx; Poloxamer 331; ANX-188; CRL-5861; P-188; Poloxamer-188; RheothRx-pf
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Bacterial infection [ICD-11: 1A00-1C4Z; ICD-10: A00-B99] | Phase 3 | [1] | |
| Non-small-cell lung cancer [ICD-11: 2C25.Y] | Phase 3 | [2] | ||
| Sickle-cell disorder [ICD-11: 3A51; ICD-10: D57.0; ICD-9: 282.6] | Phase 3 | [3] | ||
| Company |
CytRx Corp
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C5H10O2
|
|||
| Canonical SMILES |
CC1CO1.C1CO1
|
|||
| InChI |
1S/C3H6O.C2H4O/c1-3-2-4-3;1-2-3-1/h3H,2H2,1H3;1-2H2
|
|||
| InChIKey |
RVGRUAULSDPKGF-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 691397-13-4
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:32026
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00004408) Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT01737814) Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC). U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.